Takayama Koichiro, Numakura Kazuyuki, Igarashi Ryoma, Habuchi Tomonori
Department of Urology Yokote Municipal Hospital Akita Japan.
Department of Urology Akita University Graduate School of Medicine Akita Japan.
IJU Case Rep. 2022 Aug 31;5(6):517-520. doi: 10.1002/iju5.12531. eCollection 2022 Nov.
Complete remission of cerebral metastasis is a rare consequence of tyrosine kinase inhibitor monotherapy in patients with metastatic renal cell carcinoma.
A 68-year-old woman, who presented with dyspnea, was diagnosed with left renal cell carcinoma with multiple brain and pleural metastases. Although nivolumab and ipilimumab combination treatment was initiated, it was discontinued because of an immune-related adverse event. Two months after treatment cessation, brain metastases progressed regardless of shrinkage of primary renal tumor and pleural metastases. Therefore, axitinib was started as a second-line treatment, which resulted in the complete disappearance of the brain metastases along with the stable disease of the other tumor lesions.
This is the first report of complete remission of brain metastases in renal cell carcinoma treated by axitinib.
在转移性肾细胞癌患者中,酪氨酸激酶抑制剂单药治疗导致脑转移完全缓解的情况较为罕见。
一名68岁女性,因呼吸困难就诊,被诊断为左肾细胞癌伴多发脑转移和胸膜转移。尽管开始了纳武单抗和伊匹单抗联合治疗,但因免疫相关不良事件而停药。停药两个月后,尽管原发性肾肿瘤和胸膜转移灶缩小,但脑转移仍有进展。因此,开始使用阿昔替尼作为二线治疗,结果脑转移完全消失,其他肿瘤病灶病情稳定。
这是关于阿昔替尼治疗肾细胞癌脑转移完全缓解的首例报告。